The genetic polymorphism of debrisoquine/sparteine metabolism — Clinical aspects
- 31 December 1990
- journal article
- review article
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 46 (3) , 377-394
- https://doi.org/10.1016/0163-7258(90)90025-w
Abstract
No abstract availableKeywords
This publication has 96 references indexed in Scilit:
- Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI)Published by Elsevier ,2005
- POLYMORPHIC O-DEMETHYLATION OF CODEINEThe Lancet, 1988
- A human cytochrome P-450 characterized by inhibition studies as the sparteine–debrisoquine monooxygenaseCanadian Journal of Physiology and Pharmacology, 1984
- A Classification of Antiarrhythmic Actions Reassessed After a Decade of New DrugsThe Journal of Clinical Pharmacology, 1984
- Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugsLife Sciences, 1984
- Inhibition of sparteine oxidation in human liver by tricyclic antidepressants and other drugsLife Sciences, 1983
- Prediction of subclinical perhexiline neuropathy in a patient with inborn error of debrisoquine hydroxylationAmerican Heart Journal, 1983
- Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in manLife Sciences, 1980
- Hypotensive response to debrisoquine and hydroxylation phenotypeLife Sciences, 1978
- Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compoundsLife Sciences, 1967